Lymphoma Cancer

FDA Approves Keytruda for the Treatment of Relapsed/Refractory Classical Hodgkin Lymphoma

October 15th 2020, 12:30pm


Data from the trial that led to the FDA approval demonstrated that Keytruda reduced the risk of progression or death in patients with relapsed or refractory classical Hodgkin lymphoma by 35%, compared to Adcetris.

New CAR-T Cell Therapy, Given with Keytruda, Is Safe and Effective in Treating Diffuse Large B Cell Lymphoma

October 13th 2020, 1:00pm


Combining the immunotherapy Keytruda with a CAR-T cell therapy that targets the proteins CD19 and CD22 generates complete responses with minimal side effects, results from an early study demonstrate.

What the FDA’s New Breast Implant Recommendations Mean for Patients

September 30th 2020, 6:00pm


In an interview with CURE®, the president of the National Center for Health Research elaborates on the effort to protect patients from potentially serious side effects associated with getting breast implants, including breast implant-associated anaplastic large cell lymphoma.

FDA Updates Breast Implant Labeling Recommendations to Help Inform Patients About Dangerous Potential Side Effects

September 29th 2020, 5:30pm


New guidance from the Food and Drug Administration recommends that the makers of breast implants include a black-box warning, a patient decision checklist and other information on product labels that will help protect them against a cancer and an autoimmune condition that can arise from use of the devices.

New Therapies for Adults and Children With Blood Cancers Hold Promise

September 25th 2020, 9:00pm


In this special hematology focused issue of CURE® we look at all the promising treatments and research for both adults and children with blood cancers.

The Price of Hope: Weighing the Cost of CAR-T Cell Therapy in Treating Blood Cancers

September 23rd 2020, 3:00pm


Weighing the cost of CAR-T cell therapy in treating blood cancers is a finical burden for many patients with blood cancer.

What Certain Patients with DLBCL Need To Know About Monjuvi-Revlimid

September 14th 2020, 3:00pm


Patients with relapsed/refractory diffuse large B-cell lymphoma who are unable to undergo autologous stem cell transplant have a new treatment option in the combination of Monjuvi and Revlimid. The lead researcher on the study that led to the combination’s approval discusses what patients need to know.

CURE® Speaking Out Video Series Supports Blood Cancer Awareness Month and World Lymphoma Awareness Day

September 10th 2020, 9:00pm


Susan M. O’Brien, M.D., one of the nation’s foremost leukemia experts, discusses the future of frontline therapies and upcoming clinical trials associated with chronic lymphocytic leukemia.

Monjuvi-Revlimid Combination Approval Fills Unmet Need for Certain Patients with DLBCL

September 4th 2020, 6:00pm


A recent approval of the combination of Monjuvi and Revlimid fills an unmet need for certain patients with DLBCL, according to Dr. Gilles Salles.

Intensifying Rituxan for Diffuse Large B-Cell Lymphoma Treatment Does Not Improve Health Outcomes

September 2nd 2020, 9:00pm


Heightening the dose of the targeted drug Rituxan (rituximab) during the first four cycles of the R-CHOP regimen does not improve outcomes in treating patients with diffuse large B-cell lymphoma, the phase 3 HOVON-84 trial found.